UBS raised the firm’s price target on Idexx Laboratories (IDXX) to $750 from $710 and keeps a Neutral rating on the shares. The macro is showing signs of life, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- Idexx Laboratories price target raised to $830 from $785 at BTIG
- Idexx Laboratories: Strong Financial Performance and Strategic Advancements Justify Buy Rating
- IDEXX Laboratories Reports Strong Q3 2025 Results
- Idexx Laboratories price target raised to $790 from $700 at BofA
- Idexx Laboratories price target raised to $785 from $745 at Leerink